Novel Use of Targeted Therapy via PARP-Inhibition in a Rare Form of Papillary Renal Cell Carcinoma: A Case Report and Literature Review

Clin Genitourin Cancer. 2016 Aug;14(4):e445-8. doi: 10.1016/j.clgc.2016.03.012. Epub 2016 Mar 12.

¹ Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL. Electronic address: [email protected].
² Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL.
³ Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL.
⁴ Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL; Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL.

No abstract available

Keywords: Ataxia Telangiectasia Mutated; Next generation sequencing; Oncocytic Papillary Renal Cell Carcinoma; PARP inhibitor; Veliparib.

Publication types